Are Noradrenergic Transmission Reducing Drugs Antidepressants?

Abstract

Major depressive disorder (MDD) remains a significant public health problem worldwide, and revised treatment strategies are therefore urgently needed, including the creation of novel antidepressant compounds or using existing molecular entities in new ways. Etiologic theories of MDD from decades ago have suggested that synaptic deficiencies of monoaminergic neurotransmitters play a causative role in this neuropsychiatric disorder, and that boosting monoamines with drugs such as SSRIs, SNRIs, TCAs, and MAOIs has antidepressant effects and in some individuals can even induce hypomania or mania. While other factors, such as various intracellular molecular pathways and hippocampal neurogenesis, undoubtedly also play a role in MDD, monoaminergic boosting drugs nonetheless have clearly demonstrated antidepressant properties. There is also, however, a body of studies in the preclinical literature suggesting that monoaminergic transmission reducing drugs, including noradrenergic ones, also have antidepressant-like behavioral properties in rodents. Given that there is increasing evidence that the monoamines have u-shaped or Janus-faced dose-response properties, in which a mid-range value is “optimal” in a variety of behavioral and physiological processes, it is plausible that either too much or too little synaptic norepinephrine in key circuits may exacerbate MDD in some individuals. Here we briefly review rodent depression-related behavioral data, focusing on the forced swim test, from three major classes of noradrenergic transmission reducing drugs (alpha2 agonists, beta blockers, alpha1 antagonists), and find much support for the hypothesis that they have antidepressant-like properties. Whether these drugs are antidepressants in human subjects remains to be determined.

Introduction

Despite intensive efforts by commercial and academic researchers for many decades, major depressive disorder (MDD) remains a significant source of morbidity and mortality throughout the world (Chen et al., 2017; Schmaal et al., 2017; Hasin et al., 2018; Ingram et al., 2020). Many individuals who experience MDD do not respond completely, or in some cases at all, to existing pharmacological or behavioral treatment modalities, leaving a need for new approaches (Mitchell, 2004; Ruhé et al., 2006; Ulrich et al., 2020). In addition to the demand for improved psychotherapeutic treatments, the field would benefit from the creation of novel pharmacological agents or the repurposing of existing compounds that may, perhaps unexpectedly, have beneficial properties in the treatment of MDD (Ebada, 2017; Demin et al., 2019).

Following the discovery of some of today’s widely used antidepressants (MAOIs, TCAs) in the mid-20th century, monoaminergic theories on the etiology of MDD were put forth, suggesting that diminished brain levels of serotonin, norepinephrine (NE), and dopamine are a causative factor in the disorder (Schildkbaut, 1965; Coppen, 1967; Janowsky et al., 1972). In the decades since then, it has become increasingly clear that a number of intracellular molecular pathways (which undoubtedly interact with the extracellular monoamines) also play a role in MDD and the physiological and behavioral responses to antidepressant drugs (Vaidya and Duman, 2001; Tanis and Duman, 2007; Miller et al., 2009; Wohleb et al., 2016), although the continued medical use of antidepressants that boost synaptic monoamines (including SSRIs, SNRIs, NDRIs, TCAs, MAOIs) reinforces the clinical utility of this approach.

For these reasons, it may be surprising to note that in the preclinical literature there is also a significant body of studies suggesting that noradrenergic transmission reducing drugs, such as the alpha2 agonist clonidine, exhibit antidepressant-like behavioral properties under a variety of experimental conditions. This may be a surprising finding since a number of the monoaminergic theories of MDD suggest that elevated monoamines should produce mania or hypomania (Schildkbaut, 1965; Coppen, 1967; Janowsky et al., 1972), and by inference transmission reducing drugs may have mood-stabilizing properties but not necessarily be antidepressants. However, a growing body of evidence suggests that endogenous serotonin, NE, and dopamine have u-shaped or Janus-faced dose-response properties for a range of behaviors, wherein too much or too little signaling may be pathological (Baldi and Bucherelli, 2005; Arnsten, 2007; Vijayraghavan et al., 2007; Giustino et al., 2016; Giustino and Maren, 2018; Groft et al., 2019). In this scenario, perhaps a non-optimal (i.e., decreased or elevated) synaptic concentration of each monoamine may result in MDD, at least in some individuals with the disorder.

Below we briefly review rodent preclinical findings on the depression-related behavioral effects of three major classes of noradrenergic transmission reducing drugs: alpha2 agonists, beta blockers, and alpha1 antagonists. We focus on three major behavioral assays: the forced swim test (FST), the tail suspension test (TST), and the sucrose preference test. We conducted a PubMed database search using the following terms (February 7, 2021): clonidine/guanfacine/dexmedetomidine/propranolol/carvedilol/nebivolol/metoprolol/atenolol/prazosin/“beta blocker(s)”/alpha1/alpha2/beta1/beta2/beta3 +“forced swim”/“forced swimming”/“tail suspension”/“sucrose preference”/antidepressant-like/depression-like. This literature search yielded a total of 489 publications. Forty-eight were judged to be relevant articles that included data with at least one of the above types of drugs (alpha2 agonists, beta blockers, alpha1 antagonists), in mice or rats that were exposed to at least one of the above three behavioral assays (FST, TST, sucrose preference). To be included, these papers had to be published in the English language, and the 48 that met these criteria are further described in Table 1. There was no limit set on how long ago the papers were published. We did not focus on studies that investigated the interaction between natural products or compounds and these noradrenergic agents.

Alpha2 Agonists

Dating back several decades, there is a body of evidence suggesting that alpha2 adrenergic agonists such as clonidine and guanfacine, which inhibit the presynaptic release of NE and activate alpha2 receptors that are also located postsynaptically, have antidepressant-like properties in rodent models. While there are some opposing data suggesting that alpha2 antagonists can have antidepressant-like effects (Muguruza et al., 2013; Uys et al., 2017), a number of studies report that alpha2 agonists such as clonidine are therapeutic when administered acutely. A number of these studies indeed suggest that clonidine, by itself, can produce antidepressant-like effects in tests such as the FST (Malinge et al., 1988, 1989; Cervo and Samanin, 1991; Cervo et al., 1992; Asakura et al., 1993, 1994; Skrebuhhova et al., 1999; Masuda et al., 2001; O’Neill et al., 2001; Malikowska et al., 2017).

Clonidine, in many cases, when given at sub-effective doses, can also potentiate the antidepressant-like effects of a wide range of other drugs that have antidepressant properties such as SSRIs, NDRIs, TCAs, MAOIs, 5HT1A agonists, lithium, lamotrigine, and others (Malinge et al., 1988, 1989; Bourin et al., 1991, 1996; Bourin et al., 2002; Hascoät et al., 1991; Hascoet et al., 1994; Redrobe and Bourin, 1997, 1998; Skrebuhhova et al., 1999; Kaster et al., 2007; Zeidan et al., 2007; Taksande et al., 2009; Kotagale et al., 2013). In some cases these effects were shown to be counteracted by alpha2 antagonists such as idazoxan or yohimbine, suggesting clonidine achieves its antidepressant-like properties through activation of the alpha2 receptor (Malinge et al., 1988, 1989; Cervo and Samanin, 1991; Masuda et al., 2001; O’Neill et al., 2001; Zeidan et al., 2007).

In contrast to these potentially therapeutic properties of clonidine, it has also been suggested that this drug can promote depression-like behavior in rodents (Kitada et al., 1983; Parale and Kulkarni, 1986; Ferrari et al., 1991; Rénéric et al., 2002), or under some circumstances has no substantial effect either alone or when co-administered with other putative antidepressants (Kitada et al., 1983; Evangelista et al., 1987; Antkiewicz-Michaluk et al., 2017).

It has also been shown that molecular overexpression of alpha2C adrenoceptors can decrease immobility in the mouse FST (Sallinen et al., 1999), perhaps mimicking the antidepressant-like effects of alpha2 agonists such as clonidine. Antidepressant-like effects of two other alpha2 agonists, guanfacine and dexmedetomidine, have also been reported in rodent models (Stone et al., 2011; Mineur et al., 2015, 2018).

Beta Blockers

Beta blockers such as propranolol and nadolol (non-selective beta1/2 antagonists), metoprolol and atenolol (beta1), and butoxamine (beta2) can exhibit antidepressant-like activity in the FST (Chopra et al., 1988; Beĭer, 1994; Aisa et al., 2008; Park et al., 2012; Zaidi et al., 2020), including potentiation of sub-effective doses of other putative antidepressants such as baclofen (Aley and Kulkarni, 1990), or antagonizing depression-like effects of other agents (Parale et al., 1987). A mouse study of propranolol and nadolol found that whereas these two drugs did not exhibit therapeutic effects in the TST, propranolol did show an antidepressant-like decrease in TST-induced hyperthermia (Liu et al., 2003). The non-selective beta blocker nebivolol has been shown to counteract the depression-like behavioral and pathophysiological effects of the chemotherapeutic agent cisplatin (Abdelkader et al., 2017). An immunocytochemical study of propranolol showed that it could reduce the number of cells that stained for Fos-like immunoreactivity in various subcortical and cortical regions, resembling standard antidepressants such as imipramine and desipramine (Duncan et al., 1996).

In contrast to these potentially therapeutic properties of beta blockers, it has also been suggested that these drugs can promote depression-like behavior in rodents (Abel and Hannigan, 1994; Stone and Quartermain, 1999; Al-Tubuly et al., 2008) including in the presence of other putative antidepressants (Zhang et al., 2009; Gu et al., 2012), or under some circumstances, they have no substantial effect either alone or when co-administered with other putative antidepressants (Danysz et al., 1986; Evangelista et al., 1987; Finnegan et al., 1987; Teste et al., 1990; Beĭer, 1994; Detke et al., 1995; Pesarico et al., 2014; Sekio and Seki, 2015; Zaidi et al., 2020). A number of studies also suggest that the beta3 agonist amibegron (also called SR58611A) has antidepressant-like properties in rodents (Consoli et al., 2007; Overstreet et al., 2008; Stemmelin et al., 2008, 2010; Tamburella et al., 2010), and it may achieve these effects by modulating serotonergic and noradrenergic signaling that is triggered by activation of beta3 receptors (Claustre et al., 2008).

Alpha1 Antagonists

Alpha1 antagonists such as prazosin and benoxathian can also exhibit antidepressant-like activity in the FST or TST (Sekio and Seki, 2015; Kurosawa et al., 2016; Wu et al., 2017), including potentiation of other putative antidepressants such as imipramine (Al-Tubuly et al., 2008). In contrast, it has also been suggested that alpha1 antagonists can promote depression-like behavior (Stone and Quartermain, 1999; Al-Tubuly et al., 2008), including in the presence of other putative antidepressants or electroconvulsive therapy (ECT; Danysz et al., 1986; Poncelet et al., 1987; Teste et al., 1990; Kaster et al., 2007; Sugimoto et al., 2011; Gu et al., 2012; Ribeiro and Pupo, 2015). Under some circumstances they have no substantial depression-related behavioral effect either alone or when co-administered with other putative antidepressants (Evangelista et al., 1987; Malinge et al., 1988, 1989; Cervo and Samanin, 1991; Schreiber and De Vry, 1993; Detke et al., 1995; Sugimoto et al., 2011; Pesarico et al., 2014). In addition, mice expressing constitutively active mutant alpha1A (but not alpha1B) adrenoceptors exhibit antidepressant-like activity in the FST and TST, that is counteracted by prazosin (Doze et al., 2009).

Table 1 summarizes the results from, and experimental parameters used in the above rodent studies on noradrenergic transmission reducing drugs in the FST, TST, and sucrose preference test. A brief analysis of the table suggests a few prominent themes or findings: (1) clonidine is the drug with the most experimental evidence supporting an antidepressant-like role. Those data support its therapeutic-like role across a variety of both mouse and rat strains, in both the FST and TST, and an amplifying beneficial role when paired with a wide range of established antidepressants; (2) there is less support at this time of an antidepressant-like role for various beta blockers and the alpha1 antagonist prazosin, where a number of studies show depression-like effects for these drugs (although other data are supportive). These drugs appear to not have been studied as extensively in these tests as clonidine; (3) very few of the studies used female mice, which should be a priority in future studies, especially considering that the rate of MDD in women is approximately twice that in men (Baxter et al., 2014; Albert, 2015); (4) only a few of the studies used C57BL/6J mice, which are widely used in behavioral neuroscience, and could be combined with studies of additional strains of mice in further investigations; and (5) prior exposure to chronic stress, which can induce MDD in susceptible human subjects (Hosang et al., 2014; Bonde et al., 2016), was rarely used in these studies and should be further addressed with additional experiments.

Discussion

The preclinical data reviewed above address the issue of whether noradrenergic transmission reducing pharmacological agents have antidepressant-like behavioral properties in rodents. While many of these studies, perhaps most numerously and convincingly for the alpha2 agonist clonidine, suggest that these drugs have therapeutic effects, a number of the publications found no effect or depression-like effects, including for the beta blocker propranolol and the alpha1 antagonist prazosin. How do we reconcile such opposing effects across studies for these drugs? Some possibilities are that they may be due to genetic differences across strains or species of animals, varying responses to acute or chronic stress, or in some cases different behavioral tests that were used. Another explanation is that since there may be a u-shaped or Janus-faced dose-response relationship for noradrenergic signaling (Arnsten, 2007; Giustino et al., 2016; Giustino and Maren, 2018), the different drug doses used in the above studies could have opposing behavioral effects, including through interaction with divergent cortical and subcortical circuits, which may vary across species and strain. If alpha2 agonists such as clonidine and guanfacine really do have more robust antidepressant-like properties than beta blockers and alpha1 antagonists, this may relate to the more general effect of alpha2 agonists decreasing the presynaptic release of NE (Gresch et al., 1995; Van Gaalen et al., 1997), which would in principle affect signaling at all subtypes of adrenoceptors simultaneously.

A number of the studies reviewed above investigated the interaction of noradrenergic transmission reducing agents with other types of drugs. Several of these studies suggest that these noradrenergic drugs can potentiate the antidepressant-like effects of SSRIs or 5HT1A agonists (Malinge et al., 1988, 1989; Bourin et al., 1991, 1996; Hascoet et al., 1994; Redrobe and Bourin, 1997, 1998; Taksande et al., 2009), although not all studies or data were supportive (Redrobe and Bourin, 1998; Rénéric et al., 2002). Despite these discrepancies, this may be a treatment strategy that has clinical ramifications for the pharmacotherapy of MDD in human subjects. It has been previously suggested (Dremencov et al., 2007a,b; Guiard et al., 2008; Fitzgerald and Watson, 2019) that serotonin and NE may have functionally opposed properties, which is consistent with the hypothesis that noradrenergic transmission reducing drugs can amplify the effects of SSRIs under some conditions. We also suggest here, consistent with a statement in our prior publication (Polis et al., 2019), that noradrenergic transmission reducing drugs may be antidepressants in a subset of humans suffering from MDD, who would also be responsive to the rapidly acting antidepressant ketamine, and to ECT. In this scenario, noradrenergic transmission reducing agents may interact with glutamatergic signaling to chronically suppress neural hyperexcitability associated with some cases of MDD (Figure 1), and possibly have rapid therapeutic onset like ketamine (Polis et al., 2019). While the molecular mechanisms through which noradrenergic transmission reducing drugs may achieve antidepressant-like effects are not well understood at this time, one possibility is that they selectively dampen certain intracellular signaling pathways after acting upon alpha and beta-adrenergic G protein-coupled receptors. There is already evidence, for example, that NE modulates the Ras/MAPK, PI3K/Akt, JAK/STAT pathways (Muthalif et al., 1998; Yanagawa et al., 2010; Guo et al., 2013; Maity et al., 2020).

Figure 1

One might argue that noradrenergic transmission reducing drugs are, based on monoaminergic theories of mood disorders, more likely to have mood-stabilizing than antidepressant properties. After all, beta blockers such as propranolol have historically been more associated with induction of MDD or depressive-like symptomatology (Koella, 1985; Rosen and Kostis, 1985) (but also see: Kim et al., 2019; Kessing et al., 2020), or with attenuation of hypomania or mania (Emrich et al., 1979; Nemeth and Mckenzie Chustz, 2020), where the latter property has also been attributed to clonidine (Hardy et al., 1986; Nemeth and Mckenzie Chustz, 2020). One possibility is that if these drugs really are antidepressants under some conditions, they achieve these effects in individuals who exhibit neural “decoupling” of NE with dopamine in mood-related circuits. In such an individual, elevated noradrenergic signaling may result in MDD rather than dopamine-facilitated hypomania or mania (Diehl and Gershon, 1992). Since MDD is also associated with systemic inflammation (Miller et al., 2009), noradrenergic transmission reducing agents may also produce antidepressant effects by counteracting neuroinflammation (Chen et al., 2015; Ding et al., 2019; Apple et al., 2020; Figure 1).

In conclusion, while there are conflicting data in rodents as to whether noradrenergic transmission reducing drugs have antidepressant-like properties, a number of studies reviewed above support this hypothesis, at least under some experimental conditions. At present, it is not clear whether neural noradrenergic transmission is elevated or suppressed in MDD (Waldmeier, 1981), where perhaps each state exists in different individuals. For these reasons, additional preclinical, mechanistic studies are needed, including those that induce depression-like behavior in animal models through the use of chronic mild stress. Based on the foundation of preclinical studies reviewed briefly here, further investigation of noradrenergic transmission reducing drugs in human mood disorders also appears warranted.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

• 1

  AbdelkaderN. F.SaadM. A.AbdelsalamR. M. (2017). Neuroprotective effect of nebivolol against cisplatin-associated depressive-like behavior in rats. J. Neurochem.141, 449–460. 10.1111/jnc.13978

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  AbelE. L.HanniganJ. H. (1994). The immobility response in the forced swim test: paradoxical effect of imipramine. Eur. J. Pharmacol.258, 261–264. 10.1016/0014-2999(94)90488-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  AisaB.TorderaR.LasherasB.Del RíoJ.RamírezM. J. (2008). Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience154, 1218–1226. 10.1016/j.neuroscience.2008.05.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  AlbertP. R. (2015). Why is depression more prevalent in women?J. Psychiatry Neurosci.40, 219–221. 10.1503/jpn.150205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  AleyK.KulkarniS. (1990). Effect of baclofen, a GABAB-agonist, on forced swimming-induced immobility in mice. Arch. Int. Pharmacodyn. Ther.307, 18–31.

  • Pubmed Abstract
  • Google Scholar

• 6

  Al-TubulyR. A.AburawiS. M.AlghzewiE. A.GorashZ. M.ErrwamiS. (2008). The effect of sympathetic antagonists on the antidepressant action of alprazolam. Libyan J. Med.3, 78–83. 10.4176/080101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  Antkiewicz-MichalukL.RomańskaI.WąsikA.MichalukJ. (2017). Antidepressant-like effect of the endogenous neuroprotective amine, 1MeTIQ in clonidine-induced depression: behavioral and neurochemical studies in rats. Neurotox. Res.32, 94–106. 10.1007/s12640-017-9715-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  AppleC. G.MillerE. S.LoftusT. J.KannanK. B.ThompsonC. W.LopezM. C.et al. (2020). Effect of β-blockade on the expression of regulatory MicroRNA after severe trauma and chronic stress. J. Am. Coll. Surg.230, 121–129. 10.1016/j.jamcollsurg.2019.09.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  ArnstenA. F. T. (2007). Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb. Cortex17, i6–i15. 10.1093/cercor/bhm033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  AsakuraW.MatsumotoK.OhtaH.WatanabeH.AsakuraW.MatsumotoK.et al. (1993). Effect of α 2-adrenergic drugs on REM sleep deprivation-induced increase in swimming activity. Pharmacol. Biochem. Behav.46, 111–115. 10.1016/0091-3057(93)90325-n

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  AsakuraW.MatsumotoK.OhtaH.WatanabeH.MatsumotoK.OhtaH.et al. (1994). Monoamine depletion attenuates the rem sleep deprivation-induced increase in clonidine response in the forced swimming test. Pharmacol. Biochem. Behav.49, 79–84. 10.1016/0091-3057(94)90459-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  BaldiE.BucherelliC. (2005). The inverted “u-shaped” dose-effect relationships in learning and memory: modulation of arousal and consolidation. Nonlinearity Biol. Toxicol. Med.3, 9–21. 10.2201/nonlin.003.01.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  BaxterA. J.ScottK. M.FerrariA. J.NormanR. E.VosT.WhitefordH. A. (2014). Challenging the myth of an “epidemic” of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress. Anxiety31, 506–516. 10.1002/da.22230

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  BeĭerE. (1994). [A comparative evaluation of the antidepressive activity of different β-adrenoblockaders]. Eksp. Klin. Farmakol.57, 20–21.

  • Pubmed Abstract
  • Google Scholar

• 15

  BondeJ. P.Utzon-FrankN.BertelsenM.BorritzM.EllerN. H.NordentoftM.et al. (2016). Risk of depressive disorder following disasters and military deployment: systematic review with meta-analysis. Br. J. Psychiatry208, 330–336. 10.1192/bjp.bp.114.157859

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  BourinM.ColombelM.-C.MalingeM.BradwejnJ. (1991). Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J. Psychiatry Neurosci.16, 199–203.

  • Pubmed Abstract
  • Google Scholar

• 17

  BourinM.HascoëtM.ColombelM.CouttsR. T.BakerG. B. (2002). Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice. J. Psychiatry Neurosci.27, 178–185.

  • Pubmed Abstract
  • Google Scholar

• 18

  BourinM.HascoetM.ColombelM.-C.RedrobeJ. P.BakerG. B. (1996). Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Eur. Neuropsychopharmacol.6, 231–236. 10.1016/0924-977x(96)00025-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  CervoL.RossC.SamaninR. (1992). The role of serotonin and dopamine in brain in the antidepressant-like effect of clonidine in the forced swimming test. Neuropharmacology3, 331–335. 10.1016/0028-3908(92)90064-v

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20

  CervoL.SamaninR. (1991). Clonidine causes antidepressant-like effects in rats by activating a2-adrenoceptors outside the locus coeruleus. Eur. J. Pharmacol.193, 309–313. 10.1016/0014-2999(91)90144-f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  ChenY.BennettD.ClarkeR.GuoY.YuC.BianZ.et al. (2017). Patterns and correlates of major depression in Chinese adults: a cross-sectional study of 0.5 million men and women. Psychol. Med.47, 958–970. 10.1017/S0033291716002889

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  ChenX.ZhaoC.LiX.WangT.LiY.CaoC.et al. (2015). Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat. Chem. Biol.11, 19–25. 10.1038/nchembio.1657

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  ChopraK.KunchandyJ.KulkarniS. K. (1988). Benzodiazepine inverse agonist FG-7142-induced delayed behavioral depression in mice. Arch. Int. Pharmacodyn. Ther.294, 56–63.

  • Pubmed Abstract
  • Google Scholar

• 24

  ClaustreY.LeonettiM.SantucciV.BougaultI.DesvignesC.RouquierL.et al. (2008). Effects of the β3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience156, 353–364. 10.1016/j.neuroscience.2008.07.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  ConsoliD.LeggioG. M.MazzolaC.MicaleV.DragoF. (2007). Behavioral effects of the β3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?Eur. J. Pharmacol.573, 139–147. 10.1016/j.ejphar.2007.06.048

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  CoppenA. (1967). The biochemistry of affective disorders. Br. J. Psychiatry113, 1237–1264. 10.1192/bjp.113.504.1237

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  DanyszW.KostowskiW.KozakW.HauptmannM. (1986). On the role of noradrenergic neurotransmission in the action of desipramine and amitriptyline in animal models of depression. Pol. J. Pharmacol. Pharm.38, 285–298.

  • Pubmed Abstract
  • Google Scholar

• 28

  DeminK. A.SysoevM.ChernyshM. V.SavvaA. K.KoshibaM.Wappler-GuzzettaE. A.et al. (2019). Animal models of major depressive disorder and the implications for drug discovery and development. Expert Opin. Drug Discov.14, 365–378. 10.1080/17460441.2019.1575360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  DetkeM. J.WielandS.LuckiI. (1995). Blockade of the antidepressant-like effects of 8.0H-DPAT, buspirone and desipramine in the rat forced swim test by 5HTIA receptor antagonists. Psychopharmacology119, 47–54. 10.1007/BF02246053

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  DiehlD. J.GershonS. (1992). The role of dopamine in mood disorders. Compr. Psychiatry33, 115–120. 10.1016/0010-440x(92)90007-d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  DingM.ChenY.LuanH.ZhangX.ZhaoZ.WuY. (2019). Dexmedetomidine reduces inflammation in traumatic brain injury by regulating the inflammatory responses of macrophages and splenocytes. Exp. Ther. Med.18, 2323–2331. 10.3892/etm.2019.7790

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  DozeV. A.HandelE. M.JensenK. A.DarsieB.LugerE. J.HaseltonJ. R.et al. (2009). α1A- and α1B-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res.1285, 148–157. 10.1016/j.brainres.2009.06.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  DremencovE.El MansariM.BlierP. (2007a). Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology194, 63–72. 10.1007/s00213-007-0818-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  DremencovE.El MansariM.BlierP. (2007b). Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol. Psychiatry61, 671–678. 10.1016/j.biopsych.2006.05.015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  DuncanG.KnappD.JohnsonK.BreeseG. (1996). Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J. Pharmacol. Exp. Ther.277, 1076–1089.

  • Pubmed Abstract
  • Google Scholar

• 36

  EbadaM. E. (2017). Drug repurposing may generate novel approaches to treating depression. J. Pharm. Pharmacol.69, 1428–1436. 10.1111/jphp.12815

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  EmrichH. M.von ZerssenD.MöllerH. J.KisslingW.CordingC.SchietschH. J.et al. (1979). Action of propranolol in mania: comparison of effects of the d- and the l-stereoisomer. Pharmakopsychiatr. Neuropsychopharmakol.12, 295–304. 10.1055/s-0028-1094624

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  EvangelistaS.BorsiniF.MeliA. (1987). Evidence that muscimol acts in the forced swimming test by activating the rat dopaminergic system. Life Sci.41, 2679–2684. 10.1016/0024-3205(87)90283-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  FerrariF.CassinadriM.TartoniP. L.TampieriA. (1991). Effects of B-HT 920 in the tail-suspension test. Pharmacol. Res.24, 75–81. 10.1016/1043-6618(91)90067-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  FinneganK.TerwillgerM. M.BergerP. A.HolhsterL. E.CsernanskyJ. G. (1987). A comparison of the neurochemical and behavioral effects of clenbuterol and desipramine.. Eur. J. Pharmacol.134, 131–136. 10.1016/0014-2999(87)90158-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  FitzgeraldP. J.WatsonB. O. (2019). in vivo electrophysiological recordings of the effects of antidepressant drugs. Exp. Brain Res.237, 1593–1614. 10.1007/s00221-019-05556-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  GiustinoT. F.FitzgeraldP. J.MarenS. (2016). Revisiting propranolol and PTSD: memory erasure or extinction enhancement?Neurobiol. Learn. Mem.130, 26–33. 10.1016/j.nlm.2016.01.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43

  GiustinoT. F.MarenS. (2018). Noradrenergic modulation of fear conditioning and extinction. Front. Behav. Neurosci.12:43. 10.3389/fnbeh.2018.00043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  GreschP. J.SvedF.ZigroondJ.FinlayJ. M. (1995). Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem.65, 111–116. 10.1046/j.1471-4159.1995.65010111.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  GroftM. L.NormannM. C.NicklasP. R.Jagielo-MillerJ. E.McLaughlinP. J. (2019). Biphasic effects of 5-HT1A agonism on impulsive responding are dissociable from effects on anxiety in the variable consecutive number task. Naunyn Schmiedebergs Arch. Pharmacol.392, 1455–1464. 10.1007/s00210-019-01684-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  GuL.LiuY.-J.WangY.-B.YiL. T. (2012). Role for monoaminergic systems in the antidepressant-like effect of ethanol extracts from Hemerocallis citrina. J. Ethnopharmacol.139, 780–787. 10.1016/j.jep.2011.11.059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  GuiardB. P.El MansariM.MeraliZ.BlierP. (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol.11, 625–639. 10.1017/S1461145707008383

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  GuoK.MaQ.LiJ.WangZ.ShanT.LiW.et al. (2013). Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol. Cancer Ther.12, 264–273. 10.1158/1535-7163.MCT-12-0809

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  HardyM.-C.LecrubierY.WidlocherD. (1986). Efficacy of clonidine in 24 patients with acute mania. Am. J. Psychiatry143, 1450–1453. 10.1176/ajp.143.11.1450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  HascoätM.BourinM.BradwejnJ. (1991). Behavioral models in mice. implication of the α noradrenergic system. Prog. Neuropsychopharmacol. Biol. Psychiatry15, 825–840. 10.1016/0278-5846(91)90011-o

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  HascoetM.BourinM.KhimakeS. (1994). Additive effect of lithium and clonidine with 5-HT1A agonists in the forced swimming test. Prog. Neuropsychopharmacol. Biol. Psychiatry18, 381–396. 10.1016/0278-5846(94)90070-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  HasinD. S.SarvetA. L.MeyersJ. L.SahaT. D.RuanW. J.StohlM.et al. (2018). Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry75, 336–346. 10.1001/jamapsychiatry.2017.4602

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  HosangG. M.ShilesC.TanseyK. E.McGuffinP.UherR. (2014). Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med.12:7. 10.1186/1741-7015-12-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  IngramW. M.BakerA. M.BauerC. R.BrownJ. P.GoesF. S.LarsonS.et al. (2020). Defining major depressive disorder cohorts using the EHR: multiple phenotypes based on ICD-9 codes and medication orders. Neurol. Psychiatry Brain Res.36, 18–26. 10.1016/j.npbr.2020.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  JanowskyD. S.El-YousefM. K.DavisJ. M.SekerkeH. J. (1972). A cholinergic-adrenergic hypothesis of mania and depression. Lancet2, 632–635. 10.1016/s0140-6736(72)93021-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  KasterM. P.RauppI.BinfaréR. W.AndreatiniR.RodriguesA. L. S. (2007). Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system. Eur. J. Pharmacol.565, 119–124. 10.1016/j.ejphar.2007.03.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  KessingL. V.RytgaardH. C.EkstrømC. T.Torp-PedersenC.BerkM.GerdsT. A. (2020). Antihypertensive drugs and risk of depression: a nationwide population-based study. Hypertension76, 1263–1279. 10.1161/HYPERTENSIONAHA.120.15605

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  KimC.DuanL.PhanD. Q.LeeM. S. (2019). Frequency of utilization of β blockers in patients with heart failure and depression and their effect on mortality. Am. J. Cardiol.124, 746–750. 10.1016/j.amjcard.2019.05.054

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  KitadaY.MiyauchiT.KosasaT.SatohS. (1983). Further studies on the suppressing effect of isoproterenol on the immobility-reducing action of desipramine in the forced swimming test. Jpn. J. Pharmacol.33, 867–873. 10.1254/jjp.33.867

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  KoellaW. P. (1985). CNS-related (side-)effects of blockers with special reference to mechanisms of action. Eur. J. Clin. Pharmacol.28, 55–63. 10.1007/BF00543711

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  KotagaleN. R.TripathiS. J.AglaweM. M.ChopdeC. T.UmekarM. J.TaksandeB. G. (2013). Evidences for the agmatine involvement in antidepressant like effect of bupropion in mouse forced swim test. Pharmacol. Biochem. Behav.107, 42–47. 10.1016/j.pbb.2013.03.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  KurosawaN.ShimizuK.SekiK. (2016). The development of depression-like behavior is consolidated by IL-6-induced activation of locus coeruleus neurons and IL-1β-induced elevated leptin levels in mice. Psychopharmacology233, 1725–1737. 10.1007/s00213-015-4084-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  LiuX.PeprahD.GershenfeldH. K. (2003). Tail-suspension induced hyperthermia: a new measure of stress reactivity. J. Psychiatr. Res.37, 249–259. 10.1016/s0022-3956(03)00004-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  MaityS.ChandanathilM.MillisR. M.ConnorS. A. (2020). Norepinephrine stabilizes translation-dependent, homosynaptic long-term potentiation through mechanisms requiring the cAMP sensor Epac, mTOR and MAPK. Eur. J. Neurosci.52, 3679–3688. 10.1111/ejn.14735

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  MalikowskaN.FijałkowskiŁ.NowaczykA.PopikP.SałatK. (2017). Antidepressant-like activity of venlafaxine and clonidine in mice exposed to single prolonged stress—a model of post-traumatic stress disorder. Pharmacodynamic and molecular docking studies. Brain Res.1673, 1–10. 10.1016/j.brainres.2017.08.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  MalingeM.BourinM.ColombelM. C.LarousseC. (1988). Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology96, 104–109. 10.1007/BF02431541

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  MalingeM.ColombelM.BourinM. (1989). Mechanism of action of clonidine in the forced-swimming test in mice. Encephale15, 37–41.

  • Pubmed Abstract
  • Google Scholar

• 68

  MasudaY.OhnumaS.SugiyamaT. (2001). α 2-adrenoceptor activity induces the antidepressant-like glycolipid in mouse forced swimming. Methods Find. Exp. Clin. Pharmacol.23, 19–21. 10.1358/mf.2001.23.1.619175

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  MillerA. H.MaleticV.RaisonC. L. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry65, 732–741. 10.1016/j.biopsych.2008.11.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  MineurY. S.BenthamM. P.ZhouW.-L.PlantengaM. E.McKeeS. A.PicciottoM. R. (2015). Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology232, 3539–3549. 10.1007/s00213-015-4001-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  MineurY. S.CahuzacE. L.MoseT. N.BenthamM. P.PlantengaM. E.ThompsonD. C.et al. (2018). Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. Neuropsychopharmacology43, 2118–2125. 10.1038/s41386-018-0024-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  MitchellP. B. (2004). Therapeutic drug monitoring of non-tricyclic antidepressant drugs. Clin. Chem. Lab. Med.42, 1212–1218. 10.1515/CCLM.2004.243

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  MuguruzaC.RodríguezF.RozasI.MeanaJ. J.UrigüenL.CalladoL. F. (2013). Antidepressant-like properties of three new α2-adrenoceptor antagonists. Neuropharmacology65, 13–19. 10.1016/j.neuropharm.2012.09.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  MuthalifM. M.BenterI. F.KarzounN.FatimaS.HarperJ.UddinM. R.et al. (1998). 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc. Natl. Acad. Sci. U S A95, 12701–12706. 10.1073/pnas.95.21.12701

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  NemethD. G.Mckenzie ChustzK. (2020). Treating comorbid childhood bipolar disorder and ADHD. CNS Spectr.25, 283–284. 10.1017/S1092852920000486

  • CrossRef
  • Google Scholar

• 76

  O’NeillM. F.OsborneD. J.WoodhouseS. M.ConwayM. W. (2001). Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J. Psychopharmacol.15, 18–22. 10.1177/026988110101500104

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  OverstreetD. H.StemmelinJ.GriebelG. (2008). Confirmation of antidepressant potential of the selective β3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol. Biochem. Behav.89, 623–626. 10.1016/j.pbb.2008.02.020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  ParaleM. P.ChakravartiS.KulkarniS. K. (1987). Evidence of β-adrenergic involvement in forced swimming-induced behavioural despair of mice. Methods Find. Exp. Clin. Pharmacol.9, 35–38.

  • Pubmed Abstract
  • Google Scholar

• 79

  ParaleM. P.KulkarniS. K. (1986). Clonidine—induced behavioural despair in mice: reversal by antidepressants. Psychopharmacology89, 171–174. 10.1007/BF00310623

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  ParkM. J.YooS. W.ChoeB. S.DantzerR.FreundG. G. (2012). Acute hypoglycemia causes depressive-like behaviors in mice. Metab. Clin. Exp.61, 229–236. 10.1016/j.metabol.2011.06.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  PesaricoA. P.SampaioT. B.StangherlinE. C.MantovaniA. C.ZeniG.NogueiraC. W. (2014). The antidepressant-like effect of 7-fluoro-1,3-diphenylisoquinoline-1-amine in the mouse forced swimming test is mediated by serotonergic and dopaminergic systems. Prog. Neuropsychopharmacol. Biol. Psychiatry54, 179–186. 10.1016/j.pnpbp.2014.06.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  PolisA. J.FitzgeraldP. J.HaleP. J.WatsonB. O. (2019). Rodent ketamine depression-related research: finding patterns in a literature of variability. Behav. Brain Res.376:112153. 10.1016/j.bbr.2019.112153

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  PonceletM.MartinP.DantiS.SimonP.SoubriéP. (1987). Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profde of GABA agonists and imipramine-like drugs in animals. Pharmacol. Biochem. Behav.28, 321–326. 10.1016/0091-3057(87)90447-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  RedrobeJ. P.BourinM. (1997). Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundam. Clin. Pharmacol.11, 381–386. 10.1111/j.1472-8206.1997.tb00199.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  RedrobeJ. P.BourinM. (1998). Clonidine potentiates the effects of 5-HT, 5-HT and 5-HT 1A 1B 2A/2C antagonists and 8-OH-DPAT in the mouse forced swimming test. Eur. Neuropsychopharmacol.8, 169–173. 10.1016/s0924-977x(97)00073-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  RénéricJ.-P.BouvardM.StinusL. (2002). In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav. Brain Res.136, 521–532. 10.1016/s0166-4328(02)00203-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  RibeiroC. A. S.PupoA. S. (2015). Involvement of α1B-adrenoceptors in the anti-immobility effect of imipramine in the tail suspension test. Eur. J. Pharmacol.750, 39–42. 10.1016/j.ejphar.2015.01.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  RosenR.KostisJ. (1985). Biobehavioral sequellae associated with adrenergic-inhibiting antihypertensive agents: a critical review. Health Psychol.4, 579–604. 10.1037//0278-6133.4.6.579

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  RuhéH. G.HuyserJ.SwinkelsJ. A.ScheneA. H. (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry67, 1836–1855. 10.4088/jcp.v67n1203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  SallinenJ.HaapalinnaA.MacDonaldE.ViitamaaT.LähdesmäKiJ.RybnikovaE.et al. (1999). Genetic alteration of the 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry4, 443–452. 10.1038/sj.mp.4000543

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  SchildkbautJ. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry122, 509–522. 10.1176/ajp.122.5.509

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  SchmaalL.HibarD. P.SämannP. G.HallG. B.BauneB. T.JahanshadN.et al. (2017). Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA major depressive disorder working group. Mol. Psychiatry22, 900–909. 10.1038/mp.2016.60

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  SchreiberR.De VryJ. (1993). Neuroanatomical basis for the antidepressant-like effects of the 5-HT(1A) receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test. Behav. Pharmacol.4, 625–636. 10.1097/00008877-199312000-00008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  SekioM.SekiK. (2015). Lipopolysaccharide-induced depressive-like behavior is associated with α1-adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area. Int. J. Neuropsychopharmacol.18:pyu005. 10.1093/ijnp/pyu005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  SkrebuhhovaT.AllikmetsL.MattoV. (1999). Effects of anxiogenic drugs in rat forced swimming test. Methods Find. Exp. Clin. Pharmacol.21, 173–178. 10.1358/mf.1999.21.3.534826

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  StemmelinJ.CohenC.TerranovaJ.-P.Lopez-GranchaM.PichatP.BergisO.et al. (2008). Stimulation of the β3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology33, 574–587. 10.1038/sj.npp.1301424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  StemmelinJ.CohenC.YalcinI.KeaneP.GriebelG. (2010). Implication of β3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behav. Brain Res.206, 310–312. 10.1016/j.bbr.2009.09.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  StoneE. A.LinY.SarfrazY.QuartermainD. (2011). Antidepressant-like action of intracerebral 6-fluoronorepinephrine, a selective full α-adrenoceptor agonist. Int. J. Neuropsychopharmacol.14, 319–331. 10.1017/S1461145710000507

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  StoneE. A.QuartermainD. (1999). α-1-noradrenergic neurotransmission, corticosterone, and behavioral depression. Biol. Psychiatry46, 1287–1300. 10.1016/s0006-3223(99)00234-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  SugimotoY.YamamotoM.TagawaN.KobayashiY.Mitsui-SaitohK.HottaY.et al. (2011). Differences between mice strains in response to paroxetine in the forced swimming test: involvement of serotonergic or noradrenergic systems. Eur. J. Pharmacol.672, 121–125. 10.1016/j.parkreldis.2021.08.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  TaksandeB. G.KotagaleN. R.TripathiS. J.UgaleR. R.ChopdeC. T. (2009). Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology57, 415–424. 10.1016/j.neuropharm.2009.06.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  TamburellaA.MicaleV.LeggioG. M.DragoF. (2010). The β3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes. Eur. Neuropsychopharmacol.20, 704–713. 10.1016/j.euroneuro.2010.04.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  TanisK. Q.DumanR. S. (2007). Intracellular signaling pathways pave roads to recovery for mood disorders. Ann. Med.39, 531–544.10.1080/07853890701483270

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  TesteJ.MartinI.RinjardP. (1990). Electrotherapy in mice: dopaminergic and noradrenergic effects in the Tail Suspension Test. Fund. Clin. Pharmacol.4, 39–47. 10.1111/j.1472-8206.1990.tb01015.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  UlrichS.RickenR.BuspavanichP.SchlattmannP.AdliM. (2020). Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: a systematic review and comprehensive meta-analysis. J. Clin. Psychopharmacol.40, 63–74. 10.1097/JCP.0000000000001153

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  UysM. M.ShahidM.SallinenJ.HarveyB. H. (2017). The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. Behav. Pharmacol.28, 9–18. 10.1097/FBP.0000000000000261

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  VaidyaV. A.DumanR. S. (2001). Depression—emerging insights from neurobiology. Br. Med. Bull.57, 61–79. 10.1093/bmb/57.1.61

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  Van GaalenM.KawaharaH.KawaharaY.WesterinkB. (1997). The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Brain Res.763, 56–62. 10.1016/s0006-8993(97)00416-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  VijayraghavanS.WangM.BirnbaumS. G.WilliamsG. V.ArnstenA. F. T. (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci.10, 376–384. 10.1038/nn1846

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  WaldmeierP. C. (1981). Noradrenergic transmission in depression: under-or overfunction?Pharmakopsychiatria14, 3–9. 10.1055/s-2007-1019557

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  WohlebE. S.FranklinT.IwataM.DumanR. S. (2016). Integrating neuroimmune systems in the neurobiology of depression. Nat. Rev. Neurosci.17, 497–511. 10.1038/nrn.2016.69

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  WuZ. H.ZhangQ. J.DuC. X.XiY.LiW. J.GuoF. Y.et al. (2017). Prelimbic α1-adrenoceptors are involved in the regulation of depressive-like behaviors in the hemiparkinsonian rats. Brain Res. Bull.134, 99–108. 10.1016/j.brainresbull.2017.07.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  YanagawaY.MatsumotoM.TogashiH. (2010). Enhanced dendritic cell antigen uptake via α 2 adrenoceptor-mediated PI3K activation following brief exposure to noradrenaline. J. Immunol.185, 5762–5768. 10.4049/jimmunol.1001899

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  ZaidiS.AtroozF.ValdezD.LiuH.KochiC.BondR. A.et al. (2020). Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats. Neurosci. Lett.725:134892. 10.1016/j.neulet.2020.134892

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  ZeidanM. P.ZomkowskiA. D. E.RosaA. O.RodriguesA. L. S.GabilanN. H. (2007). Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur. J. Pharmacol.565, 125–131. 10.1016/j.ejphar.2007.03.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  ZhangH.-T.WhislerL. R.HuangY.XiangY.O’DonnellJ. M. (2009). Postsynaptic α-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior. Neuropsychopharmacology34, 1067–1077. 10.1038/npp.2008.184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar